Description du projet
Une avancée dans la recherche translationnelle sur le cancer en Europe
Le cancer fait 2 millions de victimes par an en Europe et coûte 100 milliards EUR. En dépit des progrès des traitements, l’efficacité des nouveaux médicaments anticancéreux dans les essais cliniques reste décevante. Le projet CARES, soutenu par le programme Actions Marie Skłodowska-Curie, entend relever ce défi. Réunissant des experts en biologie des matrices, en biomatériaux, en microfluidique et en recherche sur le cancer, CARES envisage une technologie transformatrice qui reproduit la dynamique complexe du microenvironnement tumoral humain. Axé dans un premier temps sur les cellules du cancer du sein, le projet se propose de créer une plateforme conviviale permettant de prévoir avec précision les réponses des tumeurs aux thérapies anticancéreuses. Cette avancée dans la recherche translationnelle sur le cancer promet de combler les lacunes de connaissances, de révolutionner le développement de médicaments et de profiter à la société et à l’économie.
Objectif
With 2 million cancer-related deaths and an annual cost of €100 billion, cancer constitutes a major European challenge. Cancer
treatments have considerably improved over the last decades, however, the success rate of new anti-cancer drugs in clinical trials
remains frustratingly low, limiting the opportunities for fast and accurate development of innovative targeted cancer therapies. Our
vision is to provide a bold and innovative technology that recapitulates the active part played by the human tumour
microenvironment, which has crucial roles in regulating tumour initiation, propagation, and progression, through the dynamic
crosstalk between the tumour cells and the extracellular matrix. CARES combines leading academic and non-academic experts in the
fields of matrix biology, biomaterials, microfluidics and cancer research to establish an accurate tool to assess cancer cell responses to
a variety of anti-cancer drugs. As a proof-of-concept, we will use breast cancer cells as a model system, with the perspective of
extending the system to other cancers. Our final goal is to deliver a novel and user-friendly platform that, by resembling the human
tumour microenvironment in early and advanced cancer stages, can predict, with unprecedented accuracy, the response of tumour
cells to anti-cancer therapies in vivo. This will facilitate development and testing of new drugs and narrow the gap between
translational cancer research and targeted cancer treatment, with a significant impact on society and the economy. The ambitious
scientific goal will provide the background for intense trans-sectoral and interdisciplinary training of young scientists, who will be
provided with an excellent translational research portfolio, allowing them to succeed both in academia and industry.
Champ scientifique
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Régime de financement
HORIZON-TMA-MSCA-SE - HORIZON TMA MSCA Staff ExchangesCoordinateur
48160 DERIO VIZCAYA
Espagne